Key Highlights
- TRIO Pharmaceuticals completes $3.1M financing round, led by Friedman Bioventure Fund.
- Additional support from Myeloma Investment Fund, NuFund Venture Group, and Life Science Angels.
- Funds will accelerate preclinical activities and development of TRAILBody™ and TIE-ADC™ platforms.
- Therapies target cancers with high unmet needs, including Multiple Myeloma and triple-negative breast cancer.
- Collaboration with MMRF and MIF underscores impact on oncology innovations.
Source: Business Wire
Notable Quotes
- “The TRIO team has demonstrated impressive bioactivity for both their TRAILBody and TIE-ADC bispecific antibody architectures, and we believe these potential medicines warrant accelerated development.” — Dr. Jeff Friedman, Partner at Friedman Bioventure Fund
- “TRIO’s innovative approach aligns with our mission to drive breakthrough treatments for the myeloma community. This investment underscores our commitment to accelerating therapeutic options for myeloma patients.” — Dr. Stephanie Oestreich, Managing Director at Myeloma Investment Fund
- “This financing round empowers us to expand our preclinical activities and advance our programs towards clinical development.” — Dr. Reiner Laus, CEO at TRIO Pharmaceuticals
SoHC's Take
TRIO Pharmaceuticals’ successful pre-Series A financing round highlights the growing confidence in its novel bispecific antibody therapies. The involvement of prominent investors such as Friedman Bioventure Fund and the Myeloma Investment Fund reflects the industry’s focus on precision oncology and the urgent need for innovative treatments targeting cancers with limited options. TRIO’s platforms, TRAILBody™ and TIE-ADC™, position the company as a leader in developing dual-action therapies that address tumor growth and immunosuppression simultaneously. This funding milestone is a promising step toward revolutionizing cancer care, particularly for diseases like Multiple Myeloma, where patient needs remain unmet.
